Skip to content
PeptideAI
Anecdotaljoint tendonlongevityrecovery

Sigumir

Cartilage and bone peptide extract in capsule form, taken in monthly courses by people with osteoarthritis, joint stiffness or ageing bone density concerns.

Also known as A-4, cartilage Cytomax, joints and bones peptide bioregulator, Sigumir A-4, Sigumir, Sigumir Lingual, A-4

Anecdotal — Community reports without controlled evidence. Treat the confident dosing charts accordingly.

No controlled human trials of Sigumir exist. The supporting material is manufacturer literature and Russian preclinical work on cartilage peptide fractions. Compared with collagen peptides or glucosamine, both of which at least have randomised data to argue about, Sigumir has essentially nothing.

How it works

Sigumir is peptide complex A-4, extracted from the cartilage and bone tissue of young calves at 10 mg per capsule. The claimed action is restoration of chondrocyte proliferation and proteoglycan synthesis in degenerating cartilage, plus support of osteoblast activity. The synthetic Cytogen counterpart is Cartalax, the tripeptide Ala-Glu-Asp. Note that this is a different proposition from collagen peptides, which have actual randomised human data for joint pain: Sigumir is a tissue extract sold on a gene-regulation argument, not a substrate-supply argument, and has no comparable trials.

Targets: Chondrocytes, Cartilage extracellular matrix, Osteoblasts

Dosing

ProtocolDoseFrequencyRoute
Standard capsule course10-15 minutes before a meal.10 mg – 20 mgone to two capsules daily for 10 to 30 daysoral
  • · 10 mg of peptide complex per capsule.

Cycling

Ten to thirty days per course, two to three courses a year.

Work out your exact syringe units →

Pharmacology

Half-life
Not measured after oral dosing.
Onset
Joint symptom changes, when reported, are described over three to six weeks - cartilage biology is slow regardless of what you give it.
Routes
oral, sublingual
Molecule
Bovine cartilage and bone-derived peptide complex in capsule form

Handling

Diluent
Not applicable - supplied as oral capsules.
Lyophilised
Not applicable - store capsules cool, dry and out of direct sunlight.
Reconstituted
Not applicable.
Light sensitive
Yes — keep it out of the light

Mixing

Nothing to reconstitute.

Side effects

  • uncommonMild digestive upset— Often excipient-related.
  • rareAllergic reaction to bovine protein— Animal-tissue-derived product.

Do not use if

  • Known bovine protein allergy.
  • Pregnancy and breastfeeding - no data.
  • Do not delay imaging or orthopaedic assessment of a joint that is worsening while running courses of this.

Combining it

  • synergycollagen-peptides — Collagen peptides have real randomised human data for joint pain; if you want one of the two to work, it is that one.
  • synergybpc-157 — Commonly stacked for joint complaints, though BPC-157's own evidence is rodent-only.

What to monitor

  • · Use a fixed pain and function score - WOMAC or a simple 0-10 pain scale with a defined activity - before and after each course.
  • · Range of motion measured the same way each time.

Legal status

Sold as a food supplement in Russia and much of Europe; imported elsewhere as a dietary supplement. Not an approved drug.

References

  • Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)

Mechanism in depth

There is no Sigumir-specific mechanism because there is essentially no Sigumir-specific literature - a PubMed search for the brand returns three items, none of them a study of the product. What does exist is a 2023 Russian review from Linkova's group on the ageing chondrocyte secretory phenotype and the prospects for peptide bioregulation in osteoarthritis, which frames the theoretical case, and two clinical-practice papers describing bioregulating therapy as an adjunct in temporomandibular joint disease and in dental disease in elderly patients. Those are descriptive practice reports, not controlled studies. The theoretical case is coherent enough on paper: senescent chondrocytes acquire a secretory phenotype that degrades matrix rather than building it, and a compound that restored their synthetic programme would be genuinely valuable. Nothing establishes that this capsule does that. The comparison worth keeping in view is with collagen peptides, which are also swallowed, also derived from connective tissue, and which have actual randomised trials in joint pain - but which work on a completely different premise. Collagen hydrolysates are argued to work as substrate and as a signal via absorbed hydroxyproline-containing dipeptides, at doses of 5 to 10 grams a day. Sigumir is 10 to 20 milligrams a day sold on a gene-regulation argument. Those are different orders of magnitude and different theories, and conflating them is the commonest error in this space.

What usually goes wrong

The delay problem. A worsening joint that turns out to be inflammatory arthritis, an occult fracture, avascular necrosis or a torn meniscus with mechanical locking does not improve while you run capsule courses, and some of those have treatment windows. Get imaging and an examination for a joint that is deteriorating rather than fluctuating. The second issue is expectation calibration: osteoarthritis pain varies enormously with weather, activity and mood, and a four-week course sits comfortably inside that noise, which is why the written score matters more here than for almost any other compound in this class.

Bloodwork worth running

MarkerWhenWhy it matters
hs-CRP and ESRBaseline in anyone with joint pain, particularly with morning stiffness over 30 minutes or symmetrical small-joint involvement.Not to track Sigumir, but to separate osteoarthritis from inflammatory arthritis. That distinction changes everything about treatment, and rheumatoid or psoriatic arthritis treated as wear-and-tear for a year does permanent joint damage.Act if: Raised CRP or ESR with joint symptoms means a rheumatology referral and probably rheumatoid factor, anti-CCP and imaging. Inflammatory arthritis has disease-modifying therapy with a narrow window of maximum benefit.
Serum urateBaseline, ideally not during an acute flare when urate can be falsely normal.Gout is common, intermittently presents as a single painful joint that people call arthritis, and is completely treatable. It is the diagnosis most often missed by people self-managing joint pain with supplements.Act if: Urate above about 360 micromol/L or 6 mg/dL with attacks means urate-lowering therapy, which prevents joint destruction. No peptide addresses this.
25-hydroxy vitamin DBaseline, and after three months of repletion if low.Relevant to the bone half of the claim, cheap, and actually actionable, unlike anything specific to this product.Act if: Below 50 nmol/L or 20 ng/mL warrants repletion, which has real evidence for bone health that this capsule does not.
A fixed pain and function score - WOMAC, or a 0-10 scale tied to one defined activityWeekly for four weeks before the course and four weeks after, then compare means.Not bloodwork, but joint pain fluctuates enormously week to week, and without a written baseline you will credit a good fortnight to whatever you started most recently.Act if: A change under two points on a 0-10 scale is within normal fluctuation for osteoarthritis and means nothing.

Pharmacokinetics

Metabolism
Presumed near-complete gastrointestinal proteolysis to amino acids and small fragments.
Elimination
Not characterised.

Receptor targets

  • No identified receptor or molecular target — None published

    Nothing has been characterised for this preparation.

  • Chondrocyte synthetic phenotype (claimed)

    Restoration of proliferative and proteoglycan-synthetic activity is the manufacturer claim and the subject of a 2023 theoretical review. It has not been demonstrated for this product.

What to expect, and when

Nothing acute; this is not an analgesic and will do nothing for a flare. Weeks one to three: no expected change. Weeks three to six: the window in which users report joint comfort changes, which is also the window in which osteoarthritis symptoms naturally fluctuate by a comparable margin. Months three to six: cartilage biology is slow enough that any genuine structural effect would take this long, and no imaging study of this product exists at any timepoint. Judge it on a written score across matched four-week blocks or do not judge it at all.

Stacking and comparisons

Sigumir with collagen peptides is the common stack and it is worth being clear about which component has evidence: collagen hydrolysate at 5-10 g daily has randomised trials in joint pain and skin, and Sigumir at 10-20 mg has none. If the joint feels better, that is the collagen, or the placebo effect, or the natural fluctuation of osteoarthritis. With BPC-157 the honest framing is two rodent-and-anecdote compounds stacked together. The interventions with the strongest evidence for knee osteoarthritis are not supplements at all: progressive resistance training of the quadriceps and hip, weight reduction where relevant, and topical or oral NSAIDs for flares. Any of those will outperform this capsule.

Against collagen peptides: collagen hydrolysate has multiple randomised trials in joint pain and a plausible substrate-plus-signal mechanism at gram-scale doses. Sigumir has neither the trials nor the dose. Against glucosamine and chondroitin: even these, whose large trials were largely negative, have more evidence than Sigumir does. Against exercise therapy: structured quadriceps and hip strengthening has effect sizes for knee osteoarthritis pain comparable to NSAIDs, is free, and is the single most underused intervention in the condition. Against Cartalax: the synthetic tripeptide at least has a defined molecule and a PubMed identity.

Rough cost

$70–$200/month. A 20-capsule bottle covers ten to twenty days depending on dose. Indicative pricing for the branded Russian product, not verified against vendor listings in this session.

Genuinely uncertain

  • No indexed primary study of Sigumir exists.
  • Oral bioavailability of the peptide complex has never been measured.
  • No controlled human trial of any joint or bone endpoint exists for this product.
  • Delivery to avascular articular cartilage after oral dosing is not just unmeasured, it is mechanistically difficult, and nobody has addressed the problem.
  • Composition is not published lot by lot.
  • The 2023 review discusses prospects for peptide bioregulation in osteoarthritis rather than reporting results with this preparation.
  • Cost figures are indicative estimates and were not verified against live vendor listings in this session.

Papers